Subcutaneous Anifrolumab in Adult Patients with Systemic Lupus Erythematosus

• Register: EUCTR
• Last refreshed on: 3 February 2025
• Main ID: EUCTR2020-004529-22-BG
• Date of registration: 23/07/2021
• Prospective Registration: Yes
• Primary sponsor: AstraZeneca
• Public title: Subcutaneous Anifrolumab in Adult Patients with Systemic Lupus Erythematosus
• Scientific title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Subcutaneous Anifrolumab in Adult Patients with Systemic Lupus Erythematosus - Tulip SC
• Date of first enrolment: 10/09/2021
• Target sample size: 360
• Recruitment status: Not Recruiting
• URL: https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-004529-22
• Study type: Interventional clinical trial of medicinal product
• Study design: Controlled: yes Randomised: yes Open: no Single blind: no Double blind: yes Parallel group: yes Cross over: no Other: yes Other trial design description: an OLE Period; A Follow-up Period; If controlled, specify comparator, Other Medicinial Product: no Placebo: yes Other: no Number of treatment arms in the trial: 2
• Phase: Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): no Therapeutic confirmatory - (Phase III): yes Therapeutic use (Phase IV): no

Countries of recruitment

Argentina, Bulgaria, Chile, Colombia, Germany, Hungary, Japan, Korea, Republic of, Mexico, Peru, Philippines, Poland, Russian Federation, Spain, Thailand, Ukraine, United Kingdom, United States

Contacts

• Name: Information Center
• Affiliation: AstraZeneca

• Name: Information Center
• Affiliation: AstraZeneca

Key inclusion & exclusion criteria

Inclusion criteria:
1.Patients who have a diagnosis of paediatric or adult SLE according to the ACR 1997 revised criteria for = 24 weeks prior to signing the ICF
2.To be eligible a patient must have SLEDAI-2K = 6 points and “Clinical” SLEDAI-2K score =4 points coming from clinical components ("Clinical" SLEDAI-2K") at screening. In addition, the following criteria must be met:
Clinical SLEDAI of at least = 4 points at Day 1 (randomization).
Note: The "Clinical" SLEDAI-2K is the SLEDAI-2K assessment score without the inclusion of points attributable to any urine or laboratory results including immunologic measures: Includes points from the following clinical components: arthritis, myositis, rash, alopecia, mucosal ulcers, pleurisy, pericarditis, or vasculitis. Excludes points attributed to a fever, an SLE headache, and organic brain syndrome. Clinical SLEDAI-2K points at screening cannot only be due to alopecia and mucosal ulcers.
3.At Screening, BILAG2004 with at least 1 of the following as confirmed by Disease Activity Central Team Review:
a.BILAG2004 level A disease in = 1 organ system
b.BILAG2004 level B disease in = 2 organ systems
4.Physician’s Global Assessment (PGA) score = 1.0 on a 0 to 3 VAS at Screening
5.Antinuclear antibody, and/or Anti-dsDNA and/oranti-Smith positive at Screening,
6.Must be on stable background standard therapy with therapy with antimalarials and/or immunosuppressants and glucocorticoids alone or in combination
7.Contraception Requirements
Male patients:
All fertile males who are sexually active must use condom from Day 1 until at least 16 weeks after receipt of the final dose of study intervention. It is strongly recommended that the female partner of a male patient also use an effective method of contraception from Table 9 throughout this period.
Male patients must not donate sperm during the course of the study and for 16 weeks after the last dose of the study intervention.
Female patients:
Negative serum ß-human chorionic gonadotropin (ß-hCG) test at screening (females of childbearing potential only).
Women of childbearing potential must have a negative urine pregnancy test at randomisation (Day 1), prior to administration of study intervention.
Woman of non-childbearing potential must be postmenopausal or have been surgically sterilised (for example: bilateral oophorectomy, or complete hysterectomy), which should be documented in the patient's medical records.
Age-specific requirements may apply for a postmenopausal state. Females of childbearing potential must use 1 highly effective method of contraception plus a male condom, from Screening until 16 weeks after the final dose of study intervention, unless the patient is surgically sterile (eg, bilateral oophorectomy, tubal ligation or complete hysterectomy), has a sterile male/non-fertile male partner, is at least 12 months postmenopausal, or practices sustained abstinence consistent with the patient’s customary lifestyle.
Malignancy:
Females who have been or are sexually active with an intact cervix must have ocumentation of a cervical cancer screening (Pap smear or human papilloma virus [HPV] tests as per local guidelines) with a normal test result within 2 years prior to randomisation. Any abnormal cervical cancer screening result documented within 2 years prior to randomisation must be repeated to confirm patient eligibility.
Females aged < 25 years, who have never been sexually active or have well-documented HPV vaccination records may not require a cervical c
Exclusion criteria:
1.Active severe or unstable neuropsychiatric SLE
2.Active severe SLE-driven renal disease
3.Known history of a primary immunodeficiency, splenectomy, or any underlying condition that predisposes the patient to infection, or a positive result for human immunodeficiency virus (HIV) infection confirmed by central laboratory at Screening.
4.Any severe case herpes zoster infection at any time prior to Week 0 (Day 1),
5.Opportunistic infection requiring hospitalization or IV antimicrobial treatment within 3 years of randomization.
6.History of cancer, apart from:
a. Squamous or basal cell carcinoma of the skin treated with documented success of curative therapy = 3 months prior to Week 0 (Day 1)
b. Cervical cancer in situ treated with apparent success with curative therapy = 1 year prior to Week 0 (Day 1)
7.Any history of severe COVID-19 infection eg. prolonged hospitalisation [hospitalisation for observational purposes is not exclusionary] or any prior COVID-19 infection with documented long COVID and/or clinically significant unresolved sequelae
Any mild/asymptomatic COVID-19 infection (lab confirmed or suspected based on clinical symptoms) within the last 6 weeks prior to first dosing
8.Lactating, breastfeeding or pregnant females or females who intend to become pregnant or begin
breastfeeding anytime from initiation of Screening until the end of the 16-week safety follow-up period following last dose of study intervention.


Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes

Health Condition(s) or Problem(s) studied

Therapeutic area: Diseases [C] - Immune System Diseases [C20]

Moderate-to-severe Systemic Lupus Erythematosus (SLE)
MedDRA version: 21.1 Level: PT Classification code 10042945 Term: Systemic lupus erythematosus System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders

Intervention(s)

Trade Name: SAPHNELO
Product Name: Anifrolumab
Product Code: MEDI-546
Pharmaceutical Form: Solution for injection in pre-filled syringe
INN or Proposed INN: ANIFROLUMAB
CAS Number: 1326232-46
Current Sponsor code: MEDI-546
Other descriptive name: ANIFROLUMAB
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 150-
Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe
Route of administration of the placebo: Subcutaneous use

Primary Outcome(s)

Secondary Objective: To compare the efficacy of anifrolumab with placebo on the onset of a sustained reduction in disease activity.
To compare the efficacy of anifrolumab with placebo on improvement in overall disease activity and low (or reduced) OCS use.
To compare the efficacy of anifrolumab with placebo on the onset of first flare.

Main Objective: To compare efficacy of anifrolumab with placebo on overall disease activity in patients with SLE.

Primary end point(s): BICLA a composite binary response defined by meeting all of the following criteria:
-Reduction of all baseline BILAG-2004 A to B/C/D and baseline BILAG-2004 B to C/D, and no
BILAG-2004 worsening in other organ systems, as defined by = 1 new
BILAG-2004 A or = 2 new BILAG-2004 B
-No worsening from baseline in SLEDAI-2K, where worsening is defined as an increase from baseline of > 0 points in SLEDAI-2K
-No worsening from baseline in patients' lupus disease activity, where worsening is defined by an increase = 0.30 points on a 3 point PGA VAS

Timepoint(s) of evaluation of this end point: Week 52

Secondary Outcome(s)

Secondary end point(s): 1.Proportion of patients who are BICLA responders at Week 52, and have maintained low (or reduced) OCS use through Week 52
•Maintained low (or reduced) OCS use is defined as follows:
-If baseline OCS = 10mg/day an OCS dose of = 7.5mg/day prednisone or equivalent must be achieved by Week 40 and an OCS dose = 7.5mg/day prednisone or equivalent must be maintained form Week 40 to Week 52
-If baseline OCS < 10mg/day, OCS dose at Week 40 must be less than or equal to OCS dose at baseline, with no increase from Week 40 OCS dose between Week 40 and Week 52.
2.The time from first dose of study intervention during the Double-Blind Study Period to first BICLA response sustained through week 52
3.Time to flare through Week 52 where flare is defined as either 1 or more new BILAG-2004 A or 2 or more new BILAG 2004 B items compared to the previous visit.

Timepoint(s) of evaluation of this end point: 1. at week 52
2. through week 52
2. through week 52

Secondary ID(s)

D3465C00001

2020-004529-22-HU

Source(s) of Monetary Support

AstraZeneca

Ethics review

Status: Approved
Approval date: 10/09/2021
Contact: